Лекарственная устойчивость микобактерий: эпидемиология

В обзоре представлены современные литературные данные о механизмах лекарственной устойчивости микобактерий туберкулеза (МБТ) и нетуберкулезных микобактерий (НТМБ) и о распространении туберкулеза с лекарственной устойчивостью в странах мира и регионах России, включая город Москву, в различных возрастных и социальных группах пациентов, среди впервые выявленных и ранее пролеченных больных. Описаны спектры лекарственной устойчивости МБТ в различных странах и при различных сполиготипах, а также приведены данные о лекарственной устойчивости быстро- и медленнорастущих НТМБ, полученные в городе Москве.

1. Борисов С.Е., Белиловский Е.М., Данилова И.Д., Рыбка Л.Н. Туберкулез с множественной лекарственной устойчивостью возбудителя / Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018 г. / Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. – М.: МНПЦБТ, 2019. – Гл. 5. – С. 95-105.

2. Васильева И.А., Белиловский Е.М., Борисов С.Е., Стерликов С.А. Туберкулез с множественной лекарственной устойчивостью возбудителя в странах мира и в Российской Федерации // Туберкулез и болезни легких. – 2017. – Т. 95. – № 11. – С. 5-18.

3. Галкин В.Б., Стерликов С.А., Баласанянц Г.С., Яблонский П.К. Динамика распространенности туберкулеза с множественной лекарственной устойчивостью // Туберкулез и болезни легких. – 2017. – Т. 95. – №. 3. – С. 5-12.

4. Лабораторные исследования при туберкулезе / Под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ, 2013. – 342 с.

5. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы // М.: МНПЦБТ. – 2014. – 254 c.

6. Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018 г./ Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. – М.: МНПЦБТ, 2019. – 216 с.

7. Abubakar I., Laundy M., French C., Shingadia D. Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999-2006 // Arch. Dis. Child. – 2008. – Vol. 93. – N. 12. – P. 1017-1021. doi: 10.1136/adc.2008. 139543.

8. Abubakar I., Dara M., Manissero D. et al. Tackling the spread of drug-resistant tuberculosis in Europe // Lancet. – 2012. – Vol. 379. – P. 21-23.

9. Addo K., Addo S., Mensah G. et al. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana // BMC Infect. Dis. – 2017. – Vol. 17. – N. 1. – P. 743.

10. Ahmed M., Velayati A., Mohammed S. Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries // Int. J. Mycobacteriol. – 2016. – Vol. 5. – N. 3. – P. 249-256.

11. Akkerman O., Aleksa A., Alffenaar J. et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study // Int. J. Infect. Dis. – 2019. – Vol. 83. – P. 72-76. doi: 10.1016/j.ijid.2019.03.036.

12. Al-Hajoj S., Varghese B., Shoukri M. et al. Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey // Antimicrob. Agents. Chemother. – 2013. – Vol. 57. – N. 5. – P. 2161-2166.

13. Ananta P., Kham-Ngam I., Chetchotisakd P. et al. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand // PLoS One. – 2018. – Vol. 13. – N. 11. – e0208053.

14. Appelgren A., Morquin D., Dufour S. et al. Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016 // J. Hosp. Infect. – 2017. – Vol. 97. – N. 4. – P. 414-417.

15. Barry P., Gardner T., Funk E. et al. Multistate outbreak of MDR TB identified by genotype cluster investigation // Emerging. Infect. Dis. – 2012. – Vol. 18. – P. 113-116.

16. Becerra M., Lombardía L., Lamas-Maceiras M. et al. Comparative transcriptome analysis of yeast strains carrying slt2, rlm1, and pop2 deletions // Genome. – 2011. – Vol. 54. – N. 2. – P. 99-109. doi: 10.1139/G10-101.

17. Behr M., Falinkham J. Molecular epidemiology of nontuberculous mycobacteria // Future Microbiol. – 2009. – Vol. 4. – P. 1009–1020.

18. Bloom B., Atun R., Cohen T. et al. Tuberculosis //In: Holmes K.K., Bertozzi S., Bloom B.R., Jha P., editors. Major Infectious Diseases. 3rd ed. Chapter 11. – Washington (DC): The International Bank for Reconstruction and Development / The World Bank, 2017.

19. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – Р. 545-582.

20. Cohen T., Murray M., Abubakar I. et al. Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru // Emerging. Infect. Dis. – 2011. – Vol. 17. – P. 969-975.

21. Daley C., Caminero J. Management of multidrug-resistant tuberculosis // Semin. Respir. Crit. Care Med. – 2018. – Vol. 39. – N. 3. – P. 310-324. doi: 10.1055/s-0038-1661383.

22. Dean A., Cox H., Zignol M. Epidemiology of drug-resistant tuberculosis // Adv. Exp. Med. Biol. – 2017. – Vol. 1019. – P. 209-220.

23. Devaux I., Kremer K., Heersma H. et al. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe // Emerg. Infect. Dis. – 2009. – Vol. 15. – N. 7. – P. 1052-1060.

24. Devaux I., Manissero D., Fernandez de la Hoz K. et al. Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007 // Euro. Surveill. – 2010. – Vol. 15. – N. 11. – pii: 19518.

25. Dheda K., Gumbo T., Gandhi N. et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis // Lancet. Respir. Med. – 2014. – Vol. 2. – N. 4. – P. 321-338.

26. Dheda K., Gumbo T., Maartens G. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis // Lancet. Respir. Med. – 2017. – Vol. 5. – N. 4. – P. 291-360. doi: 10.1016/S2213-2600(17)30079-6.

27. Dheda K., Limberis J., Pietersen E. et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study // Lancet. Respir. Med. – 2017. – Vol. 5. – N. 4. – P. 269-281.

28. Di Gennaro F., Pizzol D., Cebola B. et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review // Tuberculosis (Edinb). – 2017. – Vol. 103. – P. 44-51.

29. Dodd P., Sismanidis C., Seddon J. et al. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study // Lancet. Infect. Dis. – 2016. – Vol. 16. – N. 10. – P. 1193-201.

30. Dymova M., Cherednichenko A, Alkhovik O. et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia // BMC Infect. Dis. – 2014. – Vol. 3. – N. 14. – P. 478.

31. Falzon D., Schünemann H., Harausz E. et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update // Eur. Respir. J. – 2017. – Vol. 49. – N. 3. – pii: 1602308. doi: .1183/13993003.02308-2016.

32. Flores-Treviño S., Mendoza-Olazarán S., Garza-González E. Drug resistance and molecular epidemiology of Mycobacterium tuberculosis in Mexico: a systematic review // Salud. Publica. Mex. – 2014. – Vol. 56. – N. 1. – P. 63-77.

33. Flores-Treviño S., Morfín-Otero R., Rodríguez-Noriega E. et al. Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico // Enferm. Infect. Microbiol. Clin. – 2015а. – Vol. 33. – N. 3. – P. 181-185.

34. Flores-Treviño S., Morfín-Otero R., Rodríguez-Noriega E. et al. Genetic diversity of Mycobacterium tuberculosis from Guadalajara, Mexico and identification of a rare multidrug resistant Beijing genotype // PLoS One. – 2015b. – Vol. 10. – N. 2. – e0118095.

35. Fox G., Anh N., Nhung N. et al. Latent tuberculous infection in household contacts of multidrug-resistant and newly diagnosed tuberculosis // Int. J. Tuberc. Lung. Dis. – 2017. – Vol. 21. – N. 3. – P. 297-302.

36. Golla V., Snow K., Mandalakas A. et al. The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study // BMC Infect. Dis. – 2017. – Vol. 17. – P. 593.

37. Grandjean L., Iwamoto T., Lithgow A. et al. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru // PLoS One. – 2015. – Vol. 10. – N. 5. – e0126271.

38. Günther G., van Leth F., Alexandru S. et al. Multidrug-resistant tuberculosis in Europe, 2010-2011 // Emerg. Infect. Dis. – 2015. – Vol. 21. – N. 3. – P. 409-416.

39. Günther G., van Leth F., Alexandru S. et al. Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries // J. Respir. Crit. Care. Med. – 2018. – Vol. 198. – N. 3. – P. 379-386.

40. Haeili M., Darban-Sarokhalil D., Fooladi A. et al. Spoligotyping and drug resistance patterns of Mycobacterium tuberculosis isolates from five provinces of Iran // Microbiologyopen. – 2013. – Vol. 2. – N. 6. – P. 988-996.

41. Hargreaves S., Lönnroth K., Nellums L. et al. Response to Letter to the Editor by M. van der Werf, V. Hollo and C. Ködmön concerning ‘Multidrug-resistant tuberculosis and migration to Europe’ // Clin. Microbiol. Infect. – 2017. – Vol. 23. – N. 8. – P. 580. doi: 10.1016/j.cmi.2017.02.022.

42. Hasan R., Jabeen K., Mehraj V. et al. Trends in Mycobacterium tuberculosis resistance, Pakistan, 1990-2007 // Int. J. Infect. Dis. – 2009. – Vol. 13. – N. 6. – P. 377-382.

43. Hasan R., Jabeen K., Ali A. et al. Extensively drug-resistant tuberculosis, Pakistan // Emerg. Infect. Dis. – 2010. – Vol. 16., - N. 9. – P. 1473-1475.

44. Hashmi H., Javed H., Jamil N. Emerging epidemic of drug resistant tuberculosis in vulnerable populations of developing countries // Afr. Health. Sci. – 2017. – Vol. 17. – N. 2. – P. 599-602.

45. Heidarieh P., Mirsaeidi M., Hashemzadeh M. et al. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran // Microb. Drug. Resist. – 2016. – Vol. 22. – N. 2. – P. 172-178.

46. Hoffner S., Sahebi L., Ansarin K. et al. Mycobacterium tuberculosis of the Beijing genotype in Iran and the World Health Organization Eastern Mediterranean Region: a meta-analysis // Microb. Drug. Resist. – 2018. – Vol. 24. – N. 6. – P. 693-698.

47. Hu Y., Mathema B., Zhao Q. et al. Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China // Clin. Microbiol. Infect. – 2015. – Vol. 21. – N. 12. – P. 1093.

48. Huai P., Huang X., Cheng J. et al. Proportions and risk factors of developing multidrug resistance among patients with tuberculosis in China: a populationbased case-control study // Microb. Drug. Resist. – 2016. – Vol. 22. – N. 8. – P. 717-726.

49. Huo F., Luo J., Shi J. et al. A 10-year comparative analysis shows that increasing prevalence of rifampin-resistant Mycobacterium tuberculosis in China Is associated with the transmission of strains harboring compensatory mutations // Antimicrob. Agents. Chemother. – 2018. – Vol. 27. – P. 62.

50. Jenkins H., Tolman A., Yuen C. et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates // Lancet. – 2014. – Vol. 383. – N. 9928. – P. 1572-1579.

51. Johnston J., Admon A., Ibrahim A. et al. Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a low incidence setting // BMC Infect. Dis. – 2012. – Vol. 12. – P. 266.

52. Kendall E., Fofana M., Dowdy D. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis // Lancet. Respir. Med. – 2015. – Vol. 3. – P. 963-972.

53. Kodama C., Lange B., Olaru I. et al. Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis // Eur. Respir. J. – 2017. – Vol. 26. – P. 50-54.

54. Ködmön C., van den Boom M., Zucs P. et al. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015 // Euro. Surveill. – 2017. – Vol. 22. – N. 47. doi: 10.2807/1560-7917.ES.2017.22.47.17-00103.

55. Lee M., Sun P., Wu T. et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan // J. Antimicrob. Chemother. – 2017. – Vol. 72. – N. 10. – P. 2782-2786.

56. Lee R., Behr M. The implications of whole-genome sequencing in the control of tuberculosis // Ther. Adv. Infect. Dis. – 2016. - Vol. 3. – N. 2. – P. 47-62. doi: 10.1177/2049936115624630.

57. Liu H., Zhang Y., Liu Z. et al. Associations between Mycobacterium tuberculosis Beijing genotype and drug resistance to four first-line drugs: a survey in China // Front. Med. – 2018. – Vol. 12. – N. 1. – P. 92-97.

58. Loutet M., Davidson J., Brown T. et al. Acquired resistance to antituberculosis drugs in England, Wales, and Northern Ireland, 2000-2015 // Emerg. Infect. Dis. – 2018. – Vol. 24. – N. 3. – P. 524-533.

59. Lowenthal P., Lin S., Desmond E. et al. Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis //Clin. Infect. Dis. – 2019. – Vol. 69. – N. 4. – P. 668-675. https://doi.org/10.1093/cid/ciy937.

60. Lu P., Ding X., Liu Q. et al. Mediating effect of repeated tuberculosis exposure on the risk of transmission to household contacts of multidrug-resistant tuberculosis patients // Am. J. Trop. Med. Hyg. – 2018. – Vol. 98. – N. 2. – P. 364-371.

61. Luo L., Li B., Chu H. et al. Characterization of Mycobacterium Abscessus subtypes in Shanghai of China: drug sensitivity and bacterial epidemicity as well as clinical manifestations // Medicine (Baltimore). – 2016. – Vol. 95. – N. 3. – e2338.

62. McBryde E., Meehan M., Doan T. et al. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains // Int. J. Infect. Dis. – 2017. – Vol. 56. – P. 14-20.

63. Manfredi R., Nanetti A., Morelli S. et al. A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection // HIV Clin. Trials. – 2004a. – Vol. 5. – N. 4. – P. 206-215.

64. Manfredi R., Nanetti A., Valentini R. et al. Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study // HIV Med. – 2004b. – Vol. 5. – N. 6. – P. 431-436.

65. Manson A., Cohen K., Abeel T. et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance // Nat. Genet. – 2017. – Vol. 49. – N. 3. – P. 395-402.

66. Matteelli A., Centis R., D’Ambrosio L. et al. WHO strategies for the programmatic management of drug-resistant tuberculosis // Expert. Rev. Respir. Med. – 2016. – Vol. 10. – N. 9. – P. 991-1002. doi: 10.1080/17476348.2016.1199278.

67. Mesfin Y., Hailemariam D., Biadglign S. et al. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis // PLoS One. – 2014. – Vol. 9. – e82235.

68. Murase Y., Maeda S., Yamada H. et al. Clonal expansion of multidrug-resistant and extensively drug-resistant tuberculosis, Japan // Emerg. Infect. Dis. – 2010. – Vol. 16. – N. 6. – P. 948-954.

69. Nellums LB, Thompson H, Holmes A, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis // Lancet. Infect. Dis. – 2018. – Vol. 18. – N. 7. – P. 796-811.

70. Nodieva A., Jansone I., Broka L. et al. Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis // Int. J. Tuberc. Lung. Dis. – 2010. – Vol. 14. – P. 427-433.

71. Outhred A., Britton P., Marais B. Drug-Resistant tuberculosis – primary transmission and management // J. Infect. – 2017. – Vol. 74. – P. 128-135.

72. Palmero D., Cusmano L., Bucci Z. et al. Infectiousness and virulence of multidrug-resistant and drug susceptible tuberculosis in adult contacts // Medicina (B Aires). – 2002. – Vol. 62. – N. 3. – P. 221-225.

73. Pang Y., Xia H., Zhang Z. et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis // J. Clin. Microbiol. – 2013. – Vol. 51. – N. 6. – P. 1707-1713.

74. Rendon A., Centis R., D’Ambrosio L., Migliori G. WHO strategies for the management of drug-resistant tuberculosis // Arch. Bronconeumol. – 2017. – Vol. 53. – N. 3. – P. 95-97. doi: 10.1016/j.arbres.2016.07.015.

75. Rumende C. Risk factors for multidrug-resistant tuberculosis // Acta. Med. Indones. – 2018. – Vol. 50. – N. 1. – P. 1-2.

76. Sahebi L., Ansarin K., Hoffner S. et al. Molecular epidemiology of Mycobacterium tuberculosis strains in the North-West and West of Iran // Ann. Med. Health. Sci. Res. – 2015. – Vol. 5. – N. 5. – P. 334-339.

77. Seaworth B., Griffith D. therapy of multidrug-resistant and extensively drug-resistant tuberculosis // Microbiol. Spectr. – 2017. – Vol. 5. – N. 2. doi: 10.1128/microbiolspec.

78. Seddon J., Hesseling A., Marais B. et al. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa // Int. J. Tuberc. Lung. Dis. – 2012a. – Vol. 16. – N. 7. – P. 928-933.

79. Seddon J., Jordaan A., Victor T. et al. Discordant drug susceptibility for mycobacterium tuberculosis within families // Pediatr. Infect. Dis. J. – 2012b. – Vol. 31. – N. 7. – P. 783-785.

80. Seddon J., Warren R., Enarson D. et al. Drug-resistant tuberculosis transmission and resistance amplification within families // Emerg. Infect. Dis. – 2012c. – Vol. 18. – N. 8. – P. 1342-1345.

81. Seddon J., Hesseling A., Godfrey-Faussett P. et al. Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study // BMC Infect. Dis. – 2013. – Vol. 13. - P. 392.

82. Shah I. Multidrug-resistant tuberculosis in children from 2003 to 2005: a brief report // Indian. J. Med. Microbiol. – 2012. – Vol. 30. – N. 2. – P. 208-211.

83. Shah N., Yuen C., Heo M. et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis // Clin. Infect. Dis. – 2014. – Vol. 58. – N. 3. – P. 381-391.

84. Shah N., Auld S., Brust J. et al. transmission of extensively drug-resistant tuberculosis in South Africa // N. Engl. J. Med. – 2017. – Vol. 376. – N. 3. – P. 243-253.

85. Shiau M., Lee M., Huang T. et al. Mycobacterial prevalence and antibiotic resistance frequency trends in Taiwan of mycobacterial clinical isolates from 2002 to 2014 // Medicine (Baltimore). – 2016. – Vol. 95. – N. 12. – e2942.

86. Shitrit D., Baum G., Priess R. et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome // Chest. – 2006. – Vol. 129. – N. 3. – P. 771-776.

87. Smith S., Pratt R., Trieu L. et al. Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014 // Clin. Infect. Dis. – 2017. – Vol. 65. – N. 9. – P. 1437-1443.

88. Sotgiu G., D’Ambrosio L., Centis R. et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel? // Eur. Respir. J. – 2011. – Vol. 38. – P. 1221-1223.

89. Sotgiu G., Tiberi S., D’Ambrosio L. et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis // Lancet. – 2016. – Vol. 387. – N. 10037. – P. 2486-2487. doi: 10.1016/S0140-6736(16)30729-2.

90. Tanasescu M., Didilescu C., Marica C. Present and future perspectives for the rapid molecular diagnosis of TB and MDR-TB // Pneumologia. – 2013. – Vol. 62. – N. 4. – P. 198-205.

91. Tanveer M., Hasan Z., Siddiqui A. et al. Genotyping and drug resistance patterns of M. tuberculosis strains in Pakistan // BMC Infect. Dis. – 2008. – Vol. 24. – N. 8. – P. 171.

92. Tarashi S., Fateh A., Jamnani F. et al. Prevalence of Beijing and Haarlem genotypes among multidrug-resistant Mycobacterium tuberculosis in Iran: Systematic review and meta-analysis // Tuberculosis (Edinb). – 2017. – Vol. 107. – P. 31-37.

93. Teixeira L., Perkins M., Johnson J. et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis // Int. J. Tuberc. Lung. Dis. – 2001. – Vol. 5. – P. 321-328.

94. van den Hof S., Tursynbayeva A., Abildaev T. et al. HIV and multidrug-resistant tuberculosis: overlapping risk factors // Eur. Respir. J. – 2015. – Vol. 45. – P. 567-569.

95. van Ingen J., Boeree M., Wright A. et al. Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands // Int. J. Tuberc. Lung. Dis. – 2008. – Vol. 12. – N. 11. – P. 1295-1299.

96. van Ingen J., Boeree M., van Soolingen D., Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug. Resist. Updat. – 2012. – Vol. 15. – N. 3. – P. 149-161.

97. Walker T., Merker M., Knoblauch A. et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study // Lancet. Infect. Dis. – 2018. – Vol. 18. – N. 4. – P. 431-440.

98. WHO Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control // Wkly. Epidemiol. Rec. – 2006. – Vol. 81. –Р. 430-432.

99. World Health Organization (WHO). Tuberculosis MDR-TB and XDR-TB 2011 progress report. [Электронный ресурс]. URL: http://www.who.int/tb/challenges/mdr/factsheet _mdr_progress_march2011.pdf. (Дата обращения 12.09.2019).

100. World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. – Geneva:

101. WHO, 2014. [Электронный ресурс]. URL: http://apps.who.int/iris/bitstream/10665/112360/1/9789241548748_eng.pdf?ua=1. (Дата обращения 12.09.2019).

102. World Health Organization (2014a). Drug-resistant TB – surveillance and response. Supplement to global tuberculosis report 2014. WHO/HQ/TB/ 2014.12. – Geneva: WHO, 2014. [Электронный ресурс]. URL: https://www.who.int/tb/publications/global_report/gtbr14_supplement_web_v3.pdf. (Дата обращения 12.09.2019).

103. World Health Organization (2014b). Xpert MTB/RIF implementation manual. Technical and operational “how-to”: practical considerations. – Geneva: WHO, 2014. [Электронный ресурс]. URL: https://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1. (Дата обращения 12.09.2019).

104. World Health Organization (2016) Global tuberculosis report 2015. – Geneva: WHO, 2016.

105. [Электронный ресурс]. URL: http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf. (Дата обращения 12.09.2019).

106. Zhang J., Gou H., Hu X. et al. Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis // Am. J. Infect. Control. – 2016. – Vol. 44. – N. 6. – P. 671-676.

107. Zhang Z., Pang Y., Wang Y. et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China // Int. J. Antimicrob. Agents. – 2015. – Vol. 45. – N. 5. – P. 491-495.

108. Zhao X., Wang Y., Pang Y. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China // Methods. Mol. Biol. – 2015. – Vol. 1285. – P. 281-292.

109. Zignol M., Dara M., Dean A., et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data // Drug. Resist. Updat. – 2013a. – Vol. 16. – N. 6. – P. 108-115.

110. Zignol M., Sismanidis C., Falzon D. et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance // Eur. Respir. J. – 2013b. – Vol. 42. – N. 3. – P. 701-707. doi: 10.1183/09031936.00175812

111. Zürcher K., Ballif M., Fenner L. et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. International epidemiology databases to evaluate AIDS (IeDEA) consortium // Lancet Infect. Dis. – 2019. – Vol. 19. – N. 3. – P. 298-307